www.fdanews.com/articles/81867-syntonix-boehringer-deal-could-be-worth-63-million
SYNTONIX, BOEHRINGER DEAL COULD BE WORTH $63 MILLION
October 24, 2005
Syntonix Pharmaceuticals Inc., based in Waltham, and German company Boehringer Ingelheim have entered into a collaboration to optimize certain Boehringer Ingelheim therapeutic peptides for inhalation, using Syntonix's SynFusion and Transceptor technologies. Syntonix will receive an upfront fee and research support of up to $63 million.
Mass High Tech (http://www.masshightech.com/displayarticledetail.asp?Art_ID=70044)